121 related articles for article (PubMed ID: 12182873)
1. 4-Aminoquinolines as a novel class of NR1/2B subtype selective NMDA receptor antagonists.
Pinard E; Alanine A; Bourson A; Büttelmann B; Heitz M; Mutela Ramanjit Gill V; Trube G; Wyler R
Bioorg Med Chem Lett; 2002 Sep; 12(18):2615-9. PubMed ID: 12182873
[TBL] [Abstract][Full Text] [Related]
2. 1-Benzyloxy-4,5-dihydro-1H-imidazol-2-yl-amines, a novel class of NR1/2B subtype selective NMDA receptor antagonists.
Alanine A; Bourson A; Büttelmann B; Gill R; Heitz MP; Mutel V; Pinard E; Trube G; Wyler R
Bioorg Med Chem Lett; 2003 Oct; 13(19):3155-9. PubMed ID: 12951084
[TBL] [Abstract][Full Text] [Related]
3. 2-(3,4-Dihydro-1H-isoquinolin-2yl)-pyridines as a novel class of NR1/2B subtype selective NMDA receptor antagonists.
Büttelmann B; Alanine A; Bourson A; Gill R; Heitz MP; Mutel V; Pinard E; Trube G; Wyler R
Bioorg Med Chem Lett; 2003 Mar; 13(5):829-32. PubMed ID: 12617901
[TBL] [Abstract][Full Text] [Related]
4. Discovery of (R)-1-[2-hydroxy-3-(4-hydroxy-phenyl)-propyl]-4-(4-methyl-benzyl)-piperidin-4-ol: a novel NR1/2B subtype selective NMDA receptor antagonist.
Pinard E; Alanine A; Bourson A; Büttelmann B; Gill R; Heitz M; Jaeschke G; Mutel V; Trube G; Wyler R
Bioorg Med Chem Lett; 2001 Aug; 11(16):2173-6. PubMed ID: 11514163
[TBL] [Abstract][Full Text] [Related]
5. N-(2-(4-hydroxyphenyl)ethyl)-4-chlorocinnamide: a novel antagonist at the 1A/2B NMDA receptor subtype.
Tamiz AP; Whittemore ER; Schelkun RM; Yuen PW; Woodward RM; Cai SX; Weber E; Keana JF
Bioorg Med Chem Lett; 1998 Jan; 8(2):199-200. PubMed ID: 9871654
[TBL] [Abstract][Full Text] [Related]
6. 4-Hydroxy-1-[2-(4-hydroxyphenoxy)ethyl]-4-(4-methylbenzyl)piperidine: a novel, potent, and selective NR1/2B NMDA receptor antagonist.
Zhou ZL; Cai SX; Whittemore ER; Konkoy CS; Espitia SA; Tran M; Rock DM; Coughenour LL; Hawkinson JE; Boxer PA; Bigge CF; Wise LD; Weber E; Woodward RM; Keana JF
J Med Chem; 1999 Jul; 42(15):2993-3000. PubMed ID: 10425109
[TBL] [Abstract][Full Text] [Related]
7. Identification and characterization of novel NMDA receptor antagonists selective for NR2A- over NR2B-containing receptors.
Bettini E; Sava A; Griffante C; Carignani C; Buson A; Capelli AM; Negri M; Andreetta F; Senar-Sancho SA; Guiral L; Cardullo F
J Pharmacol Exp Ther; 2010 Dec; 335(3):636-44. PubMed ID: 20810618
[TBL] [Abstract][Full Text] [Related]
8. Subtype-selective antagonism of N-methyl-D-aspartate receptors by felbamate: insights into the mechanism of action.
Kleckner NW; Glazewski JC; Chen CC; Moscrip TD
J Pharmacol Exp Ther; 1999 May; 289(2):886-94. PubMed ID: 10215667
[TBL] [Abstract][Full Text] [Related]
9. Subtype-selective N-methyl-D-aspartate receptor antagonists: benzimidazalone and hydantoin as phenol replacements.
Schelkun RM; Yuen PW; Serpa K; Meltzer LT; Wise LD; Whittemore ER; Woodward RM
J Med Chem; 2000 May; 43(9):1892-7. PubMed ID: 10794706
[TBL] [Abstract][Full Text] [Related]
10. Subtype selective NMDA receptor antagonists: evaluation of some novel alkynyl analogues.
Kornberg BE; Nikam SS; Wright JL; Kesten SR; Meltzer LT; Coughenour L; Barr B; Serpa KA; McCormick J
Bioorg Med Chem Lett; 2004 Mar; 14(5):1213-6. PubMed ID: 14980668
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and biological evaluation of tricyclic heterocycle-tetraamine conjugates as potent NMDA channel blockers.
Takayama H; Yaegashi Y; Kitajima M; Han X; Nishimura K; Okuyama S; Igarashi K
Bioorg Med Chem Lett; 2007 Sep; 17(17):4729-32. PubMed ID: 17624774
[TBL] [Abstract][Full Text] [Related]
12. Subtype-selective N-methyl-D-aspartate receptor antagonists: synthesis and biological evaluation of 1-(arylalkynyl)-4-benzylpiperidines.
Wright JL; Gregory TF; Bigge CF; Boxer PA; Serpa K; Meltzer LT; Wise LD; Cai SX; Hawkinson JE; Konkoy CS; Whittemore ER; Woodward RM; Zhou ZL
J Med Chem; 1999 Jul; 42(13):2469-77. PubMed ID: 10395488
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in the development of NR2B subtype-selective NMDA receptor antagonists.
Layton ME; Kelly MJ; Rodzinak KJ
Curr Top Med Chem; 2006; 6(7):697-709. PubMed ID: 16719810
[TBL] [Abstract][Full Text] [Related]
14. Enantiomeric propanolamines as selective N-methyl-D-aspartate 2B receptor antagonists.
Tahirovic YA; Geballe M; Gruszecka-Kowalik E; Myers SJ; Lyuboslavsky P; Le P; French A; Irier H; Choi WB; Easterling K; Yuan H; Wilson LJ; Kotloski R; McNamara JO; Dingledine R; Liotta DC; Traynelis SF; Snyder JP
J Med Chem; 2008 Sep; 51(18):5506-21. PubMed ID: 18800760
[TBL] [Abstract][Full Text] [Related]
15. A comprehensive description of GluN2B-selective N-methyl-D-aspartate (NMDA) receptor antagonists.
Liu W; Jiang X; Zu Y; Yang Y; Liu Y; Sun X; Xu Z; Ding H; Zhao Q
Eur J Med Chem; 2020 Aug; 200():112447. PubMed ID: 32450321
[TBL] [Abstract][Full Text] [Related]
16. 5-Aminomethylquinoxaline-2,3-diones, Part III: Arylamide derivatives as highly potent and selective glycine-site NMDA receptor antagonists.
Acklin P; Allgeier H; Auberson YP; Bischoff S; Ofner S; Sauer D; Schmutz M
Bioorg Med Chem Lett; 1998 Mar; 8(5):493-8. PubMed ID: 9871605
[TBL] [Abstract][Full Text] [Related]
17. Parallel synthesis of a series of subtype-selective NMDA receptor antagonists.
Gregory TF; Wright JL; Wise LD; Meltzer LT; Serpa KA; Konkoy CS; Whittemore ER; Woodward RM
Bioorg Med Chem Lett; 2000 Mar; 10(6):527-9. PubMed ID: 10741546
[TBL] [Abstract][Full Text] [Related]
18. Structure-activity relationship of N-(phenylalkyl)cinnamides as novel NR2B subtype-selective NMDA receptor antagonists.
Tamiz AP; Cai SX; Zhou ZL; Yuen PW; Schelkun RM; Whittemore ER; Weber E; Woodward RM; Keana JF
J Med Chem; 1999 Aug; 42(17):3412-20. PubMed ID: 10464027
[TBL] [Abstract][Full Text] [Related]
19. Structure-activity analysis of a novel NR2C/NR2D-preferring NMDA receptor antagonist: 1-(phenanthrene-2-carbonyl) piperazine-2,3-dicarboxylic acid.
Feng B; Tse HW; Skifter DA; Morley R; Jane DE; Monaghan DT
Br J Pharmacol; 2004 Feb; 141(3):508-16. PubMed ID: 14718249
[TBL] [Abstract][Full Text] [Related]
20. Antagonists selective for NMDA receptors containing the NR2B subunit.
Chenard BL; Menniti FS
Curr Pharm Des; 1999 May; 5(5):381-404. PubMed ID: 10213801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
